TY - JOUR
T1 - Clinical and Pathological Characterization of Lynch-Like Syndrome
AU - Picó, María Dolores
AU - Castillejo, Adela
AU - Murcia, Óscar
AU - Giner-Calabuig, Mar
AU - Alustiza, Miren
AU - Sánchez, Ariadna
AU - Moreira, Leticia
AU - Pellise, María
AU - Castells, Antoni
AU - Carrillo-Palau, Marta
AU - Ramon y Cajal, Teresa
AU - Gisbert-Beamud, Alexandra
AU - Llort, Gemma
AU - Yagüe, Carmen
AU - López-Fernández, Adriá
AU - Alvarez-Urturi, Cristina
AU - Cubiella, Joaquin
AU - Rivas, Laura
AU - Rodríguez-Alcalde, Daniel
AU - Herraiz, Maite
AU - Garau, Catalina
AU - Dolz, Carlos
AU - Bujanda, Luis
AU - Cid, Lucia
AU - Povés, Carmen
AU - Garzon, Marta
AU - Salces, Inmaculada
AU - Ponce, Marta
AU - Hernández-Villalba, Luís
AU - Alenda, Cristina
AU - Balaguer, Francesc
AU - Soto, Jose Luis
AU - Jover, Rodrigo
N1 - Publisher Copyright:
© 2020 AGA Institute
PY - 2020/2
Y1 - 2020/2
N2 - Background & Aims: Lynch syndrome is characterized by DNA mismatch repair (MMR) deficiency. Some patients with suspected Lynch syndrome have DNA MMR deficiencies but no detectable mutations in genes that encode MMR proteins—this is called Lynch-like syndrome (LLS). There is no consensus on management of patients with LLS. We collected data from a large series of patients with LLS to identify clinical and pathology features. Methods: We collected data from a nationwide-registry of patients with colorectal cancer (CRC) in Spain. We identified patients whose colorectal tumors had loss of MSH2, MSH6, PMS2, or MLH1 (based on immunohistochemistry), without the mutation encoding V600E in BRAF (detected by real-time PCR), and/or no methylation at MLH1 (determined by methylation-specific multiplex ligation-dependent probe amplification), and no pathogenic mutations in MMR genes, BRAF, or EPCAM (determined by DNA sequencing). These patients were considered to have LLS. We collected data on demographic, clinical, and pathology features and family history of neoplasms. The χ2 test was used to analyze the association between qualitative variables, followed by the Fisher exact test and the Student t test or the Mann-Whitney test for quantitative variables. Results: We identified 160 patients with LLS; their mean age at diagnosis of CRC was 55 years and 66 patients were female (41%). The Amsterdam I and II criteria for Lynch syndrome were fulfilled by 11% of cases and the revised Bethesda guideline criteria by 65% of cases. Of the patients with LLS, 24% were identified in universal screening. There were no proportional differences in sex, indication for colonoscopy, immunohistochemistry, pathology findings, or personal history of CRC or other Lynch syndrome-related tumors between patients who met the Amsterdam and/or Bethesda criteria for Lynch syndrome and patients identified in universal screening for Lynch syndrome, without a family history of CRC. Conclusions: Patients with LLS have homogeneous clinical, demographic, and pathology characteristics, regardless of family history of CRC.
AB - Background & Aims: Lynch syndrome is characterized by DNA mismatch repair (MMR) deficiency. Some patients with suspected Lynch syndrome have DNA MMR deficiencies but no detectable mutations in genes that encode MMR proteins—this is called Lynch-like syndrome (LLS). There is no consensus on management of patients with LLS. We collected data from a large series of patients with LLS to identify clinical and pathology features. Methods: We collected data from a nationwide-registry of patients with colorectal cancer (CRC) in Spain. We identified patients whose colorectal tumors had loss of MSH2, MSH6, PMS2, or MLH1 (based on immunohistochemistry), without the mutation encoding V600E in BRAF (detected by real-time PCR), and/or no methylation at MLH1 (determined by methylation-specific multiplex ligation-dependent probe amplification), and no pathogenic mutations in MMR genes, BRAF, or EPCAM (determined by DNA sequencing). These patients were considered to have LLS. We collected data on demographic, clinical, and pathology features and family history of neoplasms. The χ2 test was used to analyze the association between qualitative variables, followed by the Fisher exact test and the Student t test or the Mann-Whitney test for quantitative variables. Results: We identified 160 patients with LLS; their mean age at diagnosis of CRC was 55 years and 66 patients were female (41%). The Amsterdam I and II criteria for Lynch syndrome were fulfilled by 11% of cases and the revised Bethesda guideline criteria by 65% of cases. Of the patients with LLS, 24% were identified in universal screening. There were no proportional differences in sex, indication for colonoscopy, immunohistochemistry, pathology findings, or personal history of CRC or other Lynch syndrome-related tumors between patients who met the Amsterdam and/or Bethesda criteria for Lynch syndrome and patients identified in universal screening for Lynch syndrome, without a family history of CRC. Conclusions: Patients with LLS have homogeneous clinical, demographic, and pathology characteristics, regardless of family history of CRC.
KW - Colon Tumor
KW - Familial
KW - Genetic
KW - Polyp
KW - Risk
UR - http://www.scopus.com/inward/record.url?scp=85077643040&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2019.06.012
DO - 10.1016/j.cgh.2019.06.012
M3 - Artículo
C2 - 31220642
AN - SCOPUS:85077643040
SN - 1542-3565
VL - 18
SP - 368-374.e1
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 2
ER -